Lipitor
Pfizer Sells Capsugel: Will More Asset Sales Follow?
2:15PM 4/04/2011
On Monday, Pfizer announced it would sell its Capsugel business to private-equity firm KKR for $2.375 billion. If the hints the drugmaker has been giving lately are true, the move could be the start of two years of major asset sales. Here's what's ahead for the world's biggest pharmaceutical company.
Inside Wall Street: How Goldman Is Playing the Coming Tide of Generic Drugs
7:30AM 3/02/2011
Company News, Columns, Investing, Health Care, Goldman Sachs , Stock Picks
Generic drugs are expected to enjoy a banner year in 2011, prompting some investment pros to reformulate their portfolios to get a jump on the transition. For Goldman Sachs, that means betting on several wholesale distributors and retail drugstores that stand to benefit.
In an update Tuesday, Pfizer said it is discontinuing 15 of the projects in its development pipeline. The news comes a month after the world's largest pharmaceutical company announced large research and development cuts were on the way.
The 10 Biggest-Selling Drugs That Are About to Lose Their Patent
8:00AM 2/27/2011
Company News, Investing, Health Care, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Merck, Eli Lilly, Astrazeneca
The pharmaceutical industry is ready to fall off a cliff -- a "patent cliff." Over the next few years, some of the world's most popular and lucrative medicines will go off patent, and generic competition will siphon an estimated quarter of a trillion dollars from drugmakers' bottom lines.
Pfizer Joins Other Pharmas in Giving a Cautious Outlook
3:41PM 2/01/2011
Company News, Health Care, Earnings, Pfizer, Bristol-Myers Squibb, Novartis, Eli Lilly, Astrazeneca
Pfizer reported fourth-quarter earnings on Tuesday that nearly quadrupled from a year ago as revenue rose 6%. But it also lowered its sales guidance for 2012, due to some of its bestselling drugs going off patent. What's ahead for the world's biggest drugmaker:
Counterfeit Drugs Online: What to Know and How to Protect Yourself
10:00AM 11/19/2010
Even if the fake drug you buy on the Web doesn't kill or even hurt you, the transaction itself can reveal your financial and medical information to questionable (at best) characters. Protecting yourself starts with understanding the dangers. Plus: Here are some helpful tips.
Pfizer's Potential Arthritis Drug Works in Late-Stage Trial
3:42PM 11/08/2010
Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant's report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced pain and inflammation and improved physical function in patients with moderately to severely active RA.
Pfizer Earnings Top Estimates, Boosts Guidance
7:43AM 11/02/2010
Company News, Health Care, Earnings, Pfizer, Stocks in the News
The world's biggest drugmaker reported earnings of $4.4 billion that topped estimates but revenues of $16.2 billion fell short of expectations.
For the third time in as many months, Pfizer has issued a recall of its blockbuster cholesterol drug Lipitor in response to consumer complaints of unusual moldy odor.
The drug giant said the smell poses minimal health risk to patients, but it is recalling two lots -- approximately 38,000 bottles...
Pfizer Buys King Pharma for $3.6 Billion
9:55AM 10/12/2010
Company News, Investing, Health Care, Pfizer, Stocks in the News
With King in its fold, Pfizer -- which makes Lyrica and Celebrex -- believes it can build an industry-leading portfolio of pain relievers. Among King's most appealing entrants in that market is the new Embeda, designed to prevent misuse and abuse.
More Stories
Next Page →Market Movers
| Symbol | Last | Change / % | Volume |
|---|
Most Actives
| 8.09 | -0.10 -1.16% | 144.54M | |
| 2.19 | +0.25 +12.63% | 92.86M | |
| 29.64 | -2.35 -7.35% | 23.01M | |
| 18.82 | -0.32 -1.65% | 22.24M |
% Gainers
| 32.67 | +8.77 +36.69% | 11.64M | |
| 89.23 | +12.84 +16.81% | 7.21M | |
| 2.19 | +0.25 +12.63% | 92.86M | |
| 10.56 | +1.16 +12.34% | 2.63M |
% Losers
DailyFinance Wire
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
- 5 Reasons Facebook Stock May Be a Better Buy Than You Think
Newswire
- Bernanke: Weak housing has hurt consumer...
- Turbo-traders take Bank of America for a ride
- Greece caught between protests, austerity...
- Stocks fall sharply as Greek deal is held up
- Trade deficit widens to $48.8 billion in...
- Feds investigate door fires in 2007 Camrys,...
- NYSE Euronext profit down on blocked merger...
- Obama call for manufacturing revival a tough...
- Petrobras Shares Volatile on $225 Billion Development Plan (PBR)
- Morning Movers (CIE, ALU, LNKD, AMRS, XIDE)
- AEP Dividend Growth Still Looks Safe Ahead (AEP)
- Arch Coal Tumbles on Earnings, Forecast (ACI, ANR, PCX, BTU, CNX)
- 2011 Trade Deficit Hits 3-Year High, Over $550 Billion
- Today’s Best Market Rumors (2/10/2012) Apple iPad, Google Entertainment
- Top Analyst Upgrades & Downgrades (ALTR, AMSC, BIIB, CELG, COH, CSTR, COP, FSLR, GILD, HAIN, MA, RF, TRLG)
- Morning Wire — US Stock-Index Futures Down Sharply
Follow Us
